Press Release: Incyte to Report Second Quarter Financial Results

Dow Jones

07/08

WILMINGTON, Del.--(BUSINESS WIRE)--July 08, 2026--

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.

The schedule for the press release and conference call/webcast is as follows:

   --  Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET 
 
   --  Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET 
 
   --  Domestic Dial-In Number: 877-407-3042 
 
   --  International Dial-In Number: 201-389-0864 
 
   --  Conference ID Number: 13759527

If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number 13759527.

A live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260708563739/en/

 
    CONTACT:    Incyte Contacts

Media

media@incyte.com

Investors

ir@incyte.com

(END) Dow Jones Newswires

July 08, 2026 08:02 ET

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2649995861"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649995861\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649995861?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649995861","market":"us","top_or_hot":-1,"title":"Press Release: Incyte to Report Second Quarter Financial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\nWILMINGTON, Del.--(BUSINESS WIRE)--July 08, 2026-- \n</pre>\n<p>\n     Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. \n</p>\n<p>\n     The schedule for the press release and conference call/webcast is as follows: \n</p>\n<pre style=\"white-space: pre\">\n   --  Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET \n \n   --  Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET \n \n   --  Domestic Dial-In Number: 877-407-3042 \n \n   --  International Dial-In Number: 201-389-0864 \n \n   --  Conference ID Number: 13759527 \n</pre>\n<p>\n     If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number 13759527. \n</p>\n<p>\n     A live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days. \n</p>\n<p>\n     About Incyte \n</p>\n<p>\n     Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation &amp; Autoimmunity. \n</p>\n<p>\n     To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20260708563739/en/ \n</p>\n<pre style=\"white-space: pre\">\n \n    CONTACT:    Incyte Contacts \n</pre>\n<p>\n     Media \n</p>\n<p>\n     media@incyte.com \n</p>\n<p>\n     Investors \n</p>\n<p>\n     ir@incyte.com \n</p>\n<pre style=\"white-space: pre\">\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>July 08, 2026 08:02 ET</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Incyte to Report Second Quarter Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Incyte to Report Second Quarter Financial Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-08 20:02</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\nWILMINGTON, Del.--(BUSINESS WIRE)--July 08, 2026-- \n</pre>\n<p>\n     Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. \n</p>\n<p>\n     The schedule for the press release and conference call/webcast is as follows: \n</p>\n<pre style=\"white-space: pre\">\n   --  Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET \n \n   --  Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET \n \n   --  Domestic Dial-In Number: 877-407-3042 \n \n   --  International Dial-In Number: 201-389-0864 \n \n   --  Conference ID Number: 13759527 \n</pre>\n<p>\n     If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number 13759527. \n</p>\n<p>\n     A live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days. \n</p>\n<p>\n     About Incyte \n</p>\n<p>\n     Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation &amp; Autoimmunity. \n</p>\n<p>\n     To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20260708563739/en/ \n</p>\n<pre style=\"white-space: pre\">\n \n    CONTACT:    Incyte Contacts \n</pre>\n<p>\n     Media \n</p>\n<p>\n     media@incyte.com \n</p>\n<p>\n     Investors \n</p>\n<p>\n     ir@incyte.com \n</p>\n<pre style=\"white-space: pre\">\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>July 08, 2026 08:02 ET</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"紅杉資本持倉","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649995861","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649995861","pubTimestamp":1783512120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"WILMINGTON, Del.----July 08, 2026--Incyte  announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.The schedule for the press release and conference call/webcast is as follows:--  Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4588":"碎股","IDNA":"iShares Genomics Immunology and Healthcare ETF","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓"},"translate_title":"新闻稿：Incyte将报告第二季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5,"IDNA":0.6},"content_text":"WILMINGTON, Del.--(BUSINESS WIRE)--July 08, 2026-- \n\n\n     Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. \n\n\n     The schedule for the press release and conference call/webcast is as follows: \n\n\n   --  Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET \n \n   --  Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET \n \n   --  Domestic Dial-In Number: 877-407-3042 \n \n   --  International Dial-In Number: 201-389-0864 \n \n   --  Conference ID Number: 13759527 \n\n\n     If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number 13759527. \n\n\n     A live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days. \n\n\n     About Incyte \n\n\n     Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity. \n\n\n     To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram. \n\n\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20260708563739/en/ \n\n\n \n    CONTACT:    Incyte Contacts \n\n\n     Media \n\n\n     media@incyte.com \n\n\n     Investors \n\n\n     ir@incyte.com \n\n\n \n \n\n\n  (END) Dow Jones Newswires\n\nJuly 08, 2026 08:02 ET","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}